Calistoga Pharmaceuticals is uniquely positioned to be the first company to demonstrate the clinical benefit of isoform-selective PI3 kinase inhibitors in patients with cancer and inflammatory diseases.
Calistoga Pharmaceuticals is pleased to have been selected to Fierce Biotech's Fierce 15 for 2009…read more ›
Calistoga Pharmaceuticals Reports Additional Clinical Responses in Ongoing Clinical Trial of CAL-101, an Isoform-Selective PI3 Kinase Inhibitor, Under Evaluation in Patients with Hematologic Malignancies…read more ›
